T-group (topology)
160.1.1 C-terminal domain of alpha and beta subunits of F1 ATP synthase
Ligands and drugs
5,476
Member domains
1,698
with ligand contacts (≤ 4 Å)
31.0% of members
1,478
with DrugDomain annotations
27.0% of members
1,244
with a DrugBank compound
22.7% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 160.1.1 belongs to X-group 160 C-terminal domain of alpha and beta subunits of F1 ATP synthase, which binds 3.6 ligand superclasses per 20 proteins, narrower than 93% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00171 | ATP | ATP | 904 |
| DB16833 | ADP | Adenosine disphosphate | 554 |
| DB02930 | AGS | Adenosine 5'-[gamma-thio]triphosphate | 14 |
| DB07394 | AUR | AUROVERTIN B | 5 |
| DB07347 | AES | 4-(2-Aminoethyl)Benzenesulfonyl Fluoride | 2 |
| DB07384 | — | — | 2 |
| DB08629 | — | — | 2 |
| DB00630 | — | Alendronic acid | 1 |
| DB01077 | — | Etidronic acid | 1 |
| DB05260 | — | — | 1 |
| DB06733 | — | — | 1 |
| DB06734 | — | — | 1 |
| DB11638 | — | — | 1 |
| DB12695 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 1,085 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 556 |
| ANP | PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER | 244 |
| AGS | PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER | 9 |
| MGmetal | MAGNESIUM ION | 7 |
| XBC | Cruentaren A | 4 |
| ZH7 | (3~{E},5~{E},7~{E},9~{R},10~{R},11~{E},13~{E},17~{S},18~{S},20~{S})-18-methoxy-20-[(~{R})-[(2~{R},3~{R},4~{S},5~{R},6~{R})-6-[(2~{R})-3-methoxy-2-[(2~{R},4~{S},5~{S},6~{S})-5-[(2~{S},4~{R},5~{R},6~{R})-4-methoxy-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4,6-dimethyl-4-oxidanyl-oxan-2-yl]oxy-propyl]-3,5-dimethyl-2,4-bis(oxidanyl)oxan-2-yl]-oxidanyl-methyl]-10-[(2~{R},3~{S},4~{S},5~{R},6~{S})-5-methoxy-6-methyl-3,4-bis(oxidanyl)oxan-2-yl]oxy-3,5,7,9,13-pentamethyl-17-oxidanyl-1-oxacycloicosa-3,5,7,11,13-pentaen-2-one | 4 |
| ZHD | (3~{E},5~{Z},7~{E},9~{R},10~{S},11~{E},13~{E},15~{E},17~{R},18~{S},20~{S})-20-[(1~{R})-1-[(2~{S},3~{R},4~{R},5~{S},6~{R})-5-[(2~{S},4~{S},5~{S},6~{R})-5-[(2~{S},4~{R},5~{R},6~{R})-4,6-dimethyl-4,5-bis(oxidanyl)oxan-2-yl]oxy-6-methyl-4-oxidanyl-oxan-2-yl]oxy-3-methoxy-6-(3-methoxypropyl)-5-methyl-2,4-bis(oxidanyl)oxan-2-yl]ethyl]-5,18-dimethoxy-3,7,9,11,13,15-hexamethyl-10-[(2~{R},3~{S},4~{R},5~{R},6~{S})-6-methyl-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-17-oxidanyl-1-oxacycloicosa-3,5,7,11,13,15-hexaen-2-one | 4 |
| AUR | AUROVERTIN B | 3 |
| CL | CHLORIDE ION | 2 |
| MRD | (4R)-2-METHYLPENTANE-2,4-DIOL | 2 |
| NAmetal | SODIUM ION | 2 |
| YT3metal | YTTRIUM (III) ION | 2 |
| AES | 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE | 1 |
| DCW | DICYCLOHEXYLUREA | 1 |